首页> 外文期刊>Drug discovery today >Moving forward in clinical trials for ALS: Motor neurons lead the way please
【24h】

Moving forward in clinical trials for ALS: Motor neurons lead the way please

机译:在ALS的临床试验中前进:请运动神经元引领潮流

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Amyotrophic lateral sclerosis (ALS) is one of the most complex motor neuron diseases. Even though scientific discoveries are accelerating with an unprecedented pace, to date more than 30 clinical trials have ended with failure and staggering frustration. There are too many compounds that increase life span in mice, but too little evidence that they will improve human condition. Increasing the chances of success for future clinical trials requires advancement of preclinical tests. Recent developments, which enable the visualization of diseased motor neurons, have the potential to bring novel insight. As we change our focus from mice to motor neurons, it is possible to foster a new vision that translates into effective and long-term treatment strategies in ALS and related motor neuron disorders (MND).
机译:肌萎缩性侧索硬化症(ALS)是最复杂的运动神经元疾病之一。尽管科学发现以前所未有的速度加速发展,但迄今为止,已有30多项临床试验以失败和令人沮丧的挫败告终。有太多的化合物可以延长小鼠的寿命,但是很少有证据表明它们可以改善人类的状况。增加未来临床试验成功的机会要求临床前试验的发展。最近的发展使患病的运动神经元可视化,具有带来新颖见解的潜力。当我们将注意力从小鼠转移到运动神经元时,就有可能建立新的视野,从而转变为ALS和相关运动神经元疾病(MND)的有效且长期的治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号